Quantcast

Industry news that matters to you.  Learn more

Archives for February 2014

Boehringer Ingelheim and Duke Clinical Research Institute Form Collaborative Partnership to Study the Natural History of Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

Cardiac Diagnostics Company Unveils Invitation-Only Website For Key Opinion Leaders

Critical Diagnostics recently announced the launch of ST2online.com, a free online resource designed to deliver clinical and research information specific to ST2—a cardiac biomarker that, in over 100 clinical trials has shown to be the most prognostic biomarker for improving the management of heart failure.

Cxbladder Boosting Confidence in Bladder Cancer Detection in the US

Bladder cancer patients, survivors, and families faced with life-long surveillance of the highly recurring disease are finding reassurance in Cxbladder. This new, non-invasive, urine based bladder cancer detection test developed by Pacific Edge Ltd measures the expression of five genes that create a unique molecular signature for bladder cancer, alerting doctors to possible tumors. More accurate than many other urine-based cancer detection tests, Cxbladder can give patients and doctors added confidence in their diagnoses.

bioMerieux’s THxID-BRAF Test for Detection of 2 BRAF Mutations V600E and V600K in Late-Stage Metastatic Melanoma adopted by Clarient, a GE Healthcare Company

bioMerieux, Inc. and Clarient, a GE Healthcare Company recently announced that bioMerieux’s molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient. Clarient will use THxID® BRAF in order to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline’s (GSK) Tafinlar® (dabrafenib) as well as in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist™ (trametinib).

Kiadis Pharma Initiates Collaboration for Personalized Immunotherapies Using ATIR with Technische Universität München within Munich Biotech Cluster

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, recently announced that it has initiated a collaboration to identify and characterize leukemia-specific T-cells in Kiadis Pharma’s lead product ATIR, that would be responsible for the Graft-versus-Leukemia effect of the T-cell immunotherapy product. The collaboration will be run with Prof. Dr. Angela Krackhardt who leads the group of Translational Immunotherapy at the Department of Hematology (Prof. Christian Peschel) of the Klinikum rechts der Isar of the Technische Universität München.